2024
Viral antibody response predicts morbidity and mortality in alcohol-associated hepatitis.
Hsu C, Wang L, Maestri E, Jacob A, Do W, Mayo S, Bosques-Padilla F, Verna E, Abraldes J, Brown R, Vargas V, Altamirano J, Caballería J, Shawcross D, Louvet A, Lucey M, Mathurin P, Garcia-Tsao G, Stärkel P, Bataller R, Investigators A, Wang X, Schnabl B. Viral antibody response predicts morbidity and mortality in alcohol-associated hepatitis. Hepatology 2024 PMID: 39325984, DOI: 10.1097/hep.0000000000001046.Peer-Reviewed Original ResearchAlcohol-associated hepatitisAlcohol use disorderHigher Child-Pugh scoreSerological profileAntibody responseAssociated with very high mortalityUse disorderDecompensation of liver diseaseChild-Pugh scoreActive alcohol useNinety-day mortalityAssociated with decompensationMulticenter observational studyViral antibody responseMonths of diagnosisAntibody repertoireSera of patientsMultiorgan dysfunctionPoor prognosisNinety-daySerological biomarkersHealthy controlsPatient seraLiver diseaseAntibody targeting
2021
Admission Urinary and Serum Metabolites Predict Renal Outcomes in Hospitalized Patients With Cirrhosis
Bajaj JS, Garcia‐Tsao G, Reddy KR, O’Leary J, Vargas HE, Lai JC, Kamath PS, Tandon P, Subramanian RM, Thuluvath P, Fagan A, Sehrawat T, de la Rosa Rodriguez R, Thacker LR, Wong F. Admission Urinary and Serum Metabolites Predict Renal Outcomes in Hospitalized Patients With Cirrhosis. Hepatology 2021, 74: 2699-2713. PMID: 34002868, PMCID: PMC9338693, DOI: 10.1002/hep.31907.Peer-Reviewed Original ResearchConceptsAcute kidney injuryPrediction of AKIClinical variablesSerum/urineSerum metabolitesBranched-chain amino acid metabolitesLiver disease centerNorth American ConsortiumRole of serumAmino acid metabolitesAdmission urinaryAKI developmentAKI subgroupCirrhosis cohortRenal outcomesRenoprotective measuresKidney injuryAKI predictionCirrhosis severityDialysis initiationHospitalized patientsPoor prognosisUrine metabolomicsEarly initiationSpecific admission
2011
Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1*
Boyer TD, Sanyal AJ, Garcia‐Tsao G, Regenstein F, Rossaro L, Appenrodt B, Gülberg V, Sigal S, Bexon AS, Teuber P, Group T. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1*. Liver Transplantation 2011, 17: 1328-1332. PMID: 21837734, PMCID: PMC3760727, DOI: 10.1002/lt.22395.Peer-Reviewed Original ResearchConceptsHepatorenal syndrome type 1Liver transplantationHepatorenal syndromeSyndrome type 1Nontransplant patientsTransplant patientsSurvival benefitSurvival rateType 1Pretransplant renal functionUse of terlipressinClear survival benefitCohort of patientsSurvival of patientsHRS reversalPosttransplant managementLiver transplantPosttransplant survivalMost patientsPosttransplant outcomesRenal functionPoor prognosisTerlipressinPatientsTransplantation